Schizophrenia Bulletin Advance Access originally published online on February 15, 2006
Schizophrenia Bulletin 2006 32(2):214-219; doi:10.1093/schbul/sbj053
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2006. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.
The NIMH-MATRICS Consensus Statement on Negative Symptoms
2 Department of Psychiatry and Health Behavior, Medical College of Georgia
3 Division of Adult Translational Research and Development, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services
4 Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland
5 VA Desert Pacific (VISN 22), Mental Illness Research, Education, and Clinical Center, Department of Psychiatry, David Geffen School of Medicine, University of California, Los Angeles
Keywords: schizophrenia / methods / clinical trials / rating scales / antipsychotics
| The first 150 words of the full text of this article appear below. |
The impairments now called negative symptoms have long been noted as common features of schizophrenia, and the concept of negative symptoms itself has a long history.1,2 Patients who exhibit significant negative symptoms have particularly poor function and quality of life,3–8 and this aspect of schizophrenia has been proposed as a separate domain with distinctive pathophysiological and therapeutic implications since at least 1974.9 Despite the attention these problems receive, no drug has received Food and Drug Administration (FDA) approval for an indication of negative symptoms, and available data indicate that second-generation antipsychotic medications have not met early hopes for a highly effective treatment for alleviation of negative symptoms.10
Because of limited progress in the development of effective treatments for negative symptoms, under the auspices of the National Institute of Mental Health (NIMH), Drs. Steve Marder, Wayne Fenton, William T. Carpenter, Jr, and Brian Kirkpatrick initiated a process to examine issues that
 |
Areas of Agreement |
|---|
|
Unresolved Issues and Future Directions |
|---|
|
Conclusion |
|---|
|
Appendix |
|---|
Participants in the Consensus Development Conference
Presentations at the Consensus Development Conference on Negative Symptoms, January 26–27, 2005
1To whom correspondence should be addressed; e-mail: bkirkpatrick2@aol.com.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. M. P. O'Tuathaigh, B. P. Kirby, P. M. Moran, and J. L. Waddington Mutant Mouse Models: Genotype-Phenotype Relationships to Negative Symptoms in Schizophrenia Schizophr Bull, November 24, 2009; (2009) sbp125v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Faerden, S. Friis, I. Agartz, E. A. Barrett, R. Nesvag, A. Finset, and I. Melle Apathy and Functioning in First-Episode Psychosis Psychiatr Serv, November 1, 2009; 60(11): 1495 - 1503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Moscarelli Passive and Active Schizophrenia: Toward a New Descriptive Micropsychopathology Schizophr Bull, November 1, 2009; 35(6): 1183 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Grant and A. T. Beck Defeatist Beliefs as a Mediator of Cognitive Impairment, Negative Symptoms, and Functioning in Schizophrenia Schizophr Bull, July 1, 2009; 35(4): 798 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. I. Elmer and N. Kafkafi Drug Discovery in Psychiatric Illness: Mining for Gold Schizophr Bull, March 18, 2009; (2009) sbn194v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Kern, S. M. Glynn, W. P. Horan, and S. R. Marder Psychosocial Treatments to Promote Functional Recovery in Schizophrenia Schizophr Bull, March 1, 2009; 35(2): 347 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Carpenter A Few Methodologic Issues of Note Schizophr Bull, November 1, 2008; 34(6): 1003 - 1005. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Gold, J. A. Waltz, K. J. Prentice, S. E. Morris, and E. A. Heerey Reward Processing in Schizophrenia: A Deficit in the Representation of Value Schizophr Bull, September 1, 2008; 34(5): 835 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Barch Emotion, Motivation, and Reward Processing in Schizophrenia Spectrum Disorders: What We Know and Where We Need to Go Schizophr Bull, September 1, 2008; 34(5): 816 - 818. [Full Text] [PDF]
|
|
|
|
|
|
G. Foussias and G. Remington Negative Symptoms in Schizophrenia: Avolition and Occam's Razor Schizophr Bull, July 21, 2008; (2008) sbn094v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Cuesta and V. Peralta Current Psychopathological Issues in Psychosis: Towards a Phenome-wide Scanning Approach Schizophr Bull, July 1, 2008; 34(4): 587 - 590. [Full Text] [PDF]
|
|
|
|
|
|
A. S. Cohen and K. S. Minor Emotional Experience in Patients With Schizophrenia Revisited: Meta-analysis of Laboratory Studies Schizophr Bull, June 17, 2008; (2008) sbn061v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Melle, T. K. Larsen, U. Haahr, S. Friis, J. O. Johannesen, S. Opjordsmoen, B. R. Rund, E. Simonsen, P. Vaglum, and T. McGlashan Prevention of Negative Symptom Psychopathologies in First-Episode Schizophrenia: Two-Year Effects of Reducing the Duration of Untreated Psychosis Arch Gen Psychiatry, June 1, 2008; 65(6): 634 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Carpenter and R. W. Buchanan Lessons to Take Home From CATIE Psychiatr Serv, May 1, 2008; 59(5): 523 - 525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Curtis, K. Katsafouros, H-J. Moller, R. Medori, and E. Sacchetti Long-acting risperidone improves negative symptoms in stable psychotic patients J Psychopharmacol, May 1, 2008; 22(3): 254 - 261. [Abstract] [PDF]
|
|
|
|
 |
|
 S. R. Marder Neurocognition as a Treatment Target in Schizophrenia Focus, April 1, 2008; 6(2): 180 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Bibliography Schizophrenia Focus, April 1, 2008; 6(2): 197 - 199. [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Owens How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia Adv. Psychiatr. Treat., January 1, 2008; 14(1): 17 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-C. Ho, N. C. Andreasen, J. D. Dawson, and T. H. Wassink Association Between Brain-Derived Neurotrophic Factor Val66Met Gene Polymorphism and Progressive Brain Volume Changes in Schizophrenia Am J Psychiatry, December 1, 2007; 164(12): 1890 - 1899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. RUHRMANN, A. BECHDOLF, K.-U. KUHN, M. WAGNER, F. SCHULTZE-LUTTER, B. JANSSEN, K. MAURER, H. HAFNER, W. GAEBEL, H.-J. MOLLER, et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis The British Journal of Psychiatry, December 1, 2007; 191(51): s88 - s95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Buchanan, D. C. Javitt, S. R. Marder, N. R. Schooler, J. M. Gold, R. P. McMahon, U. Heresco-Levy, and W. T. Carpenter The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and Cognitive Impairments Am J Psychiatry, October 1, 2007; 164(10): 1593 - 1602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Breier, L. Alphs, and B. Binneman Commentary: Wayne Fenton's Impact on Industry Schizophr Bull, September 1, 2007; 33(5): 1154 - 1155. [Full Text] [PDF]
|
|
|
|
|
|
T. H. McGlashan and W. T. Carpenter Identifying Unmet Therapeutic Domains in Schizophrenia Patients: The Early Contributions of Wayne Fenton From Chestnut Lodge Schizophr Bull, September 1, 2007; 33(5): 1086 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Stover, S. Marder, and W. Carpenter Progress on NIMH Initiatives (Memorial Theme for Wayne Fenton, MD) Schizophr Bull, September 1, 2007; 33(5): 1084 - 1085. [Full Text] [PDF]
|
|
|
|
|
|
R. W. Buchanan Persistent Negative Symptoms in Schizophrenia: An Overview Schizophr Bull, July 1, 2007; 33(4): 1013 - 1022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Erickson, J. R. Ciccone, S. B. Schwarzkopf, J. S. Lamberti, and M. J. Vitacco Legal Fallacies of Antipsychotic Drugs J Am Acad Psychiatry Law, June 1, 2007; 35(2): 235 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Bellack, M. F. Green, J. A. Cook, W. Fenton, P. D. Harvey, R. K. Heaton, T. Laughren, A. C. Leon, D. J. Mayo, D. L. Patrick, et al. Assessment of Community Functioning in People With Schizophrenia and Other Severe Mental Illnesses: A White Paper Based on an NIMH-Sponsored Workshop Schizophr Bull, May 1, 2007; 33(3): 805 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Shepard Editorial--Modeling Negative Symptoms: What's Missing? Schizophr Bull, July 1, 2006; 32(3): 403 - 404. [Full Text] [PDF]
|
|